Tristel, the Suffolk based supplier of infection and contamination control products, reported the release of three pieces of further scientific evidence for Tristel products:
- A report on disinfectants from the Health Protection Agency Microbiological Services, Porton Down, concluded that six out of seven of the most effective and fastest acting disinfectants tested were Tristel chlorine dioxide products.
- A urological study comparing Tristel Fuse and Johnson & Johnson's Cidex OPA for use with flexible cystoscopes found that both products had comparable efficacy, but Tristel Fuse was by far the most cost effective and quickest to use.
- A study from University College London Hospitals NHS Trust presented to the UK Infection Prevention Society conference in October 2011 reported upon the adoption throughout all five hospitals in this major London Trust of Tristel's surface disinfectants in replacement of the chlorine tablets previously used.
To access an interview with the CEO of Tristel, Paul Swinney, conducted by Stockopedia click here.
The TSTL share price has decreased by 41% over the last year.
Tristel Plc is graded b by LCF Research. To learn more, follow the link.
